Please assess the completion status of the following clinical trial:

Trial Title: Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must have the diagnosis of hypothyroidism.~* Patients must be already on thyroid hormone replacement.~* Patients must be greater than or equal to 18 years old.~* Patients must have a diagnosis of a primary or secondary brain tumor and must have received prior radiation.~* Patients must have a life expectancy of at least 6 months.~Exclusion Criteria:~* Previously established dementing illness.~* Other medical conditions known to cause dementia.~* Significant psychiatric illness.~* Uncontrolled seizures.~* Acute or chronic pulmonary disease.~* Active severe infections.~* Signs or symptoms of coronary artery disease.~* History of congenital hypothyroidism, hyperthyroidism, thyroidectomy, 131I-therapy, or thyroid cancer.~* Paroxysmal supraventricular tachycardia, or any serious unstable medical condition.~* Inability to read and write in English.~* Patients must not be taking any medications that interfere with thyroid hormone metabolism (Beta-Adrenergic Blocking Agents, Antiarrhythmic drugs, Antipsychotic Agents, Tricyclic Antidepressants, Amiodarone, Iodine, Lithium, and Alpha-Interferon).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levothyroxine + Liothyronine (Type: EXPERIMENTAL): Levothyroxine 75 mcg by mouth (PO) Daily for 8 Weeks + Liothyronine 15 mcg PO Daily for 8 Weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).